NEW YORK (GenomeWeb) –Definiens and MolecularMD said today that they will partner to provide customized diagnostic solutions in oncology.
Definiens specializes in what it calls "tissue phenomics" for biomarker and companion diagnostics development and commercialization. MolecularMD develops custom molecular diagnostic products and supports clinical trial services for targeted cancer therapies.
Under the partnership, the companies plan to combine MolecularMD's expertise in specialty diagnostic assays with Definiens' quantitative tissue read-outs in order to provide custom solutions that meet data and regulatory requirements for both biopharmaceutical clients and academic medical center oncology programs.
"This agreement brings together MolecularMD's proven track record in clinical assay development and companion diagnostics with Definiens' unparalleled image analysis platform to provide the confidence of an integrated solution in stratifying patients," Definiens chief commercial officer Merrilyn Datta said in a statement.